Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 836845 plus exemestane and everolimus versus exemestane and everolimus in HR-positive/HER2-negative advanced or metastatic breast cancer
NL-OMON43947Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2016
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of xentuzumab, exemestane and everolimus in breast cancer (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Progression-free survival. Started Sep 2016; status: active, not recruiting.
02
Drugs
xentuzumabexemestaneeverolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON43947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43947.